Grifols acquires Alkahest Inc.

Grifols announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional financing will be required. The closing of the transaction is subject to the approval by the relevant antitrust authorities, and is expected to close in early 2021. The Silicon Valley-based biotechnology company was founded upon research into the therapeutic use of plasma proteins in combating diseases associated with aging as identified in the Stanford University laboratory of Tony Wyss-Coray, professor of Neurology at Stanford and co-founder and board member of Alkahest.